Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market 2012-2016

Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market 2012-2016

Category : Healthcare

TOLL FREE
+1-971-202-1575
------------ Or -------------
help@researchbeam.com

TechNavio's analysts forecast the Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs market to grow at a CAGR of 3 percent over the period 2012–2016. One of the key factors contributing to this market growth is the increase in prevalence of the MRSA infection. The Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs market has also been witnessing the increase in Governmental/Non-Governmental awareness programs. However, the increasing generic competition could pose a challenge to the growth of this market. 

TechNavio's report, the Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market 2012–2016, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

The key vendors dominating this market space are Pfizer Inc., Cubist Pharmaceuticals Inc., ViroPharma Inc., Theravance Inc. and Forest Laboratories Inc.

The other vendors mentioned in the report are Basilea Pharmaceutica Ltd., Durata Therapeutics, Inc., Novartis AG, Trius Therapeutics, Inc., AstraZeneca plc., and GlaxoSmithKline plc. 

Key questions answered in this report: 
What will the market size be in 2016 and what will the growth rate be?
What are the key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the market opportunities and threats faced by the key vendors?
What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.

1. Executive Summary

2. List of Abbreviations

3. Introduction

4. Market Research Methodology


4.1. Market Research Process

4.2. Research Design

4.3. Research Methodology

5. Scope of the Report

5.1. Market Overview

5.2. Product Offerings

6. Market Landscape

6.1. Global Cephalosporin Drugs Market 

6.1.1. Market Size and Forecast 

7. Five Force Analysis

8. Geographical Segmentation

9. Vendor Landscape

10. Buying Criteria

11. Market Growth Drivers

12. Drivers and their Impact

13. Market Challenges

14. Impact of Drivers and Challenges

15. Market Trends

16. Key Vendor Analysis


16.1. Pfizer Inc.

16.1.1. Business Overview

16.1.2. Key Information

16.1.3. SWOT Analysis

16.2. Cubist Pharmaceuticals Inc.

16.2.1. Business Overview

16.2.2. Key Information

16.2.3. SWOT Analysis

16.3. ViroPharma Inc.

16.3.1. Business Overview

16.3.2. Key Information

16.3.3. SWOT Analysis

16.4. Forest Laboratories Inc.

16.4.1. Business Overview

16.4.2. Key Information

16.4.3. SWOT Analysis

16.5. Theravance Inc.

16.5.1. Business Overview

16.5.2. Key Information

16.5.3. SWOT Analysis



17. Other Reports in this Series



List of Exhibits:

Exhibit 1: Market Research Methodology

Exhibit 2: Global Methicillin-resistant Staphylococcus aureus (MRSA) Drugs 2012-2016 (US$ millions)

Exhibit 3: Global Methicillin-resistant Staphylococcus aureus (MRSA) Drugs Market by Geographical Segmentation 2012

Exhibit 4: Global Methicillin-resistant Staphylococcus aureus (MRSA) Drugs Market by Vendor Segmentation 2012



Enquiry Before Buy